Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA

NCT04517864 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04517864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
September 15, 2020
Completion date
May 7, 2024
Enrollment
71 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata